Literature DB >> 11465149

Enzyme kinetics of cytochrome P450-mediated reactions.

M Shou1, Y Lin, P Lu, C Tang, Q Mei, D Cui, W Tang, J S Ngui, C C Lin, R Singh, B K Wong, J A Yergey, J H Lin, P G Pearson, T A Baillie, A D Rodrigues, T H Rushmore.   

Abstract

The most common drug-drug interactions may be understood in terms of alterations of metabolism, associated primarily with changes in the activity of cytochrome P450 (CYP) enzymes. Kinetic parameters such as Km, Vmax, Ki and Ka, which describe metabolism-based drug interactions, are usually determined by appropriate kinetic models and may be used to predict the pharmacokinetic consequences of exposure to one or multiple drugs. According to classic Michaelis-Menten (M-M) kinetics, one binding site models can be employed to simply interpret inhibition (pure competitive, non-competitive and uncompetitive) or activation of the enzyme. However, some cytochromes P450, in particular CYP3A4, exhibit unusual kinetic characteristics. In this instance, the changes in apparent kinetic constants in the presence of inhibitor or activator or second substrate do not obey the rules of M-M kinetics, and the resulting kinetics are not straightforward and hamper mechanistic interpretation of the interaction in question. These unusual kinetics include substrate activation (autoactivation), substrate inhibition, partial inhibition, activation, differential kinetics and others. To address this problem, several kinetic models can be proposed, based upon the assumption that multiple substrate binding sites exist at the active site of a particular P450, and the resulting kinetic constants are, therefore, solved to adequately describe the observed interaction between multiple drugs. The following is an overview of some cytochrome P450-mediated classic and atypical enzyme kinetics, and the associated kinetic models. Applications of these kinetic models can provide some new insights into the mechanism of P450-mediated drug-drug interactions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11465149     DOI: 10.2174/1389200013338784

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  13 in total

Review 1.  Dietary effects on drug metabolism and transport.

Authors:  Robert Z Harris; Graham R Jang; Shirley Tsunoda
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.

Authors:  Jin Zhou; Timothy S Tracy; Rory P Remmel
Journal:  Drug Metab Dispos       Date:  2010-10-28       Impact factor: 3.922

3.  In vitro and in vivo glucuronidation of midazolam in humans.

Authors:  Ruth Hyland; Toby Osborne; Anthony Payne; Sarah Kempshall; Y Raj Logan; Khaled Ezzeddine; Barry Jones
Journal:  Br J Clin Pharmacol       Date:  2009-04       Impact factor: 4.335

Review 4.  In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions.

Authors:  Stephen Fowler; Hongjian Zhang
Journal:  AAPS J       Date:  2008-08-07       Impact factor: 4.009

5.  Mixing apples and oranges: Analysis of heterotropic cooperativity in cytochrome P450 3A4.

Authors:  Daniel J Frank; Ilia G Denisov; Stephen G Sligar
Journal:  Arch Biochem Biophys       Date:  2009-06-26       Impact factor: 4.013

6.  Surface plasmon resonance analysis of antifungal azoles binding to CYP3A4 with kinetic resolution of multiple binding orientations.

Authors:  Josh T Pearson; John J Hill; Jennifer Swank; Nina Isoherranen; Kent L Kunze; William M Atkins
Journal:  Biochemistry       Date:  2006-05-23       Impact factor: 3.162

7.  Dose-dependent exposure and metabolism of GNE-892, a β-secretase inhibitor, in monkeys: contributions by P450, AO, and P-gp.

Authors:  Ryan Takahashi; Shuguang Ma; Qin Yue; Heasook Kim-Kang; Yijun Yi; Joseph P Lyssikatos; Kelly Regal; Kevin W Hunt; Nicholas C Kallan; Michael Siu; Cornelis E C A Hop; Xingrong Liu; S Cyrus Khojasteh
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-04-03       Impact factor: 2.441

8.  Kinetics of PKCε activating and inhibiting llama single chain antibodies and their effect on PKCε translocation in HeLa cells.

Authors:  Milla Summanen; Niko Granqvist; Raimo K Tuominen; Marjo Yliperttula; C Theo Verrips; Johannes Boonstra; Christophe Blanchetot; Elina Ekokoski
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

9.  An in silico transwell device for the study of drug transport and drug-drug interactions.

Authors:  Lana X Garmire; David G Garmire; C Anthony Hunt
Journal:  Pharm Res       Date:  2007-08-17       Impact factor: 4.580

10.  Explaining the atypical reaction profiles of heme enzymes with a novel mechanistic hypothesis and kinetic treatment.

Authors:  Kelath Murali Manoj; Arun Baburaj; Binoy Ephraim; Febin Pappachan; Pravitha Parapurathu Maviliparambathu; Umesh K Vijayan; Sivaprasad Valiyaveettil Narayanan; Kalaiselvi Periasamy; Ebi Ashley George; Lazar T Mathew
Journal:  PLoS One       Date:  2010-05-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.